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Abstract
Background: The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to
mutations in the phosphatidylinositol 3-kinase (PI3K) pathway. Targeting mTOR with allosteric inhibitors of mTOR
such as rapamycin reduces colon cancer progression in several experimental models. Recently, a new class of
mTOR inhibitors that act as ATP-competitive inhibitors of mTOR, has been developed. The effectiveness of these
drugs in colon cancer cells has however not been fully characterized.
Methods: LS174T, SW480 and DLD-1 colon cancer cell lines were treated with PP242 an ATP-competitive inhibitor
of mTOR, NVP-BEZ235, a dual PI3K/mTOR inhibitor or rapamycin. Tumor cell growth, proliferation and survival were
assessed by MTS assay, 5-bromo-2’-deoxyuridine (BrDU) incorporation or by quantification of DNA fragmentation
respectively. In vivo, the anticancer activity of mTOR inhibitors was evaluated on nude mice bearing colon cancer
xenografts.
Results: PP242 and NVP-BEZ235 reduced the growth, proliferation and survival of LS174T and DLD-1 colon cancer
cells more efficiently than rapamycin. Similarly, PP242 and NVP-BEZ235 also decreased significantly the proliferation
and survival of SW480 cells which were resistant to the effects of rapamycin. In vivo, PP242 and NVP-BEZ235
reduced the growth of xenografts generated from LS174T and SW480 cells. Finally, we also observed that the
efficacy of ATP-competitive inhibitors of mTOR was enhanced by U0126, a MEK inhibitor.
Conclusions: Taken together, these results show that ATP-competitive inhibitors of mTOR are effective in blocking
colon cancer cell growth in vitro and in vivo and thus represent a therapeutic option in colon cancer either alone
or in combination with MEK inhibitors.
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Background
Colorectal cancer (CRC) is one of the leading cause of
cancer-related deaths worldwide [1]. Over the last dec-
ade, new therapeutic options for the treatment of CRC
have been developed including targeted therapies. For
example, drugs that block the vascular endothelial
growth factor or the epidermal growth factor receptor
have shown clinical activities and have been approved
for the treatment of CRC [2]. However, despite these
new treatments, the prognosis of CRC remains poor and
new therapeutic strategies still need to be explored.
The mammalian target of rapamycin (mTOR) is a ser-
ine/threonine kinase, present in two functionally distinct
complexes mTORC1 and mTORC2. While mTORC1 is
composed of mTOR, mLST8, raptor, deptor and
PRAS40, mTORC2 consists of mTOR, rictor protor,
mLST8, deptor and sin1 [3,4]. mTORC1 regulates cell
growth by controlling mRNA translation initiation and
progression by phosphorylating two well characterized
downstream effectors: S6K1 and 4E-BP1 [5]. In addition,
mTORC1 also regulates ribosome biogenesis, autophagy
and lipid biosynthesis. mTORC2 is involved in cell sur-
vival and proliferation by phosphorylating members of
the AGC kinase family including Akt, protein kinase C
and serum-and glucocorticoid-regulated kinase [6-8]. Of
note, whereas mTORC1 is sensitive to acute exposure to
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cells, prolonged exposure to rapamycin also inhibits
mTORC2 [9].
Emerging data have shown that mTOR is implicated
in the progression of CRC and represents a promising
target in the treatment of CRC. Indeed, components of
mTOR signaling pathway are frequently activated or
over-expressed in CRC [10,11]. For example, genetic
aberrations of the catalytic subunit of the phosphatidy-
linositol 3-kinase (PI3K), an upstream effector of
mTORC1 and mTORC2, are frequent in colon cancer
[12,13].Moreover, the inhibition of mTOR signals by
allosteric inhibitors such as rapamycin or small interfer-
ing RNA has been shown to reduce colon cancer growth
in different experimental settings [10,11,14,15]. Recently,
a new class of mTOR inhibitors have been developed
that target the kinase domain of mTOR and referred as
ATP-competitive inhibitors of mTOR [16,17]. In con-
trast to rapamycin which targets only certain functions
of mTORC1, ATP-competitive inhibitors of mTOR inhi-
bit both mTORC1 and mTORC2. Furthermore, a subset
of these inhibitors also blocks PI3K in addition to inhi-
bit mTORC1 and mTORC2 [18]. In this study, we have
determined the anticancer activity of PP242 [19], a
kinase inhibitor of mTOR and NVP-BEZ235 [20], a dual
PI3K/mTOR inhibitor, in colon cancer cells, both in
vitro and in vivo.
Methods
Cell lines, antibodies and reagents
The human colon cancer cell lines LS174T, DLD-1,
SW480, SW620, HT29, Caco-2, and HCT-116 were
maintained in Dulbecco’s modified eagle’sm e d i u ms u p -
plemented with 10% fetal calf serum. Antibodies direc-
ted against phospho-Akt (Ser473), Akt, phospho-S6
ribosomal protein (Ser235/236), S6 ribosomal protein
and cleaved caspase-3 were from Cell signaling technol-
ogy (Danvers, MA, USA). Rapamycin, U0126 and NVP-
BEZ235 were from LC laboratories (Woburn, MA,
USA). PP242 was from Chemdea (Ridgewood, NJ, USA).
For in vitro experiments, all inhibitors were dissolved in
dimethyl sulfoxide (DMSO).
Western blot analysis
Western blot were performed as previously described
[21].
MTS proliferation assay
LS174T, SW480, DLD-1, Caco-2, HCT-116, SW620 and
HT-29 cells were plated on 96-well plates (Costar) at
10’000 cells per well and cultured in DMEM 10% FBS.
Twelve hours later, cells were treated with rapamycin (10
nM), NVP-BEZ235 (100 nM), PP242 (100 nM) or DMSO
as a control. Cellular proliferation was monitored after
48 hours of treatment with the CellTiter 96
® Aqueous
One Solution (Promega Corporation) colorimetric assay
by following the manufacturer’s instructions.
BrDU incorporation assay
BrDU incorporation assay was performed as previously
described [22].
Cell survival studies
LS174T, SW480, DLD-1 cells were plated in 96-well
plates at 30,000 cells per well. Twelve hours later, cells
were treated with rapamycin (10 nM), NVP-BEZ235 (100
nM), PP242 (100 nM), either alone or in combination
with U0126 (10 μM) for 48 hours. Subsequently cells
were harvested and apoptosis was determined using the
Cell Death Detection ELISA plus kit (Roche) and follow-
ing the manufacturer’s instructions. Results are repre-
sented as the mean enrichment factor (absorbance of the
treated cells/absorbance of the control cells).
In addition, cell apoptosis was also quantified using
flow cytometry. LS174T, SW480 and DLD-1 cells were
plated in 6-well plates at 300 000 cells per well and trea-
ted as above. After 48 hours of treatment cells were col-
lected and fixed in 70% ethanol for 24 hours. Cells were
subsequently resuspended in phosphate buffered saline
(PBS) containing 20 μg/ml propidium iodide and 200
μg/ml RNAse and incubated for 30 minutes at 37°C.
The percentages of sub-G1 population were determined
by flow cytometry.
Tumor xenografts
Animal experiments were approved by the ethics com-
mittee of the cantonal veterinary office of Canton Vaud
(Authorization 2047) and conducted in accordance with
the regulations of the Service of Consumables and
Veterinary Affairs-Division of Animal Protection
( S C A V - E X P A N I M ) .F e m a l en u d em i c ea g e d8w e e k s
were purchased from Charles River (Charles River
Laboratories, St. Germain sur l’A r b r e s l e ,F r a n c e ) .O n e
million LS174T or SW480 cells were injected subcuta-
neously into the flank of nude mice. Once the tumor
xenografts reached 25 mm
3, mice were randomized into
different groups (n = 5 in each group). Mice were trea-
ted with rapamycin (1.5 mg/kg/d, i.p.), NVP-BEZ235
(30 mg/kg/d, p.o.), PP242 (60 mg/kg/d, p.o.) either alone
or in combination with U0126 (40 μmol/kg/d, i.p.).
All mice received both p.o. and i.p. doses of vehicle to
control for morbidity associated with treatment. NVP-
BEZ235 was solubilized in one volume of N-methylpyr-
rolidone and further diluted in nine volumes of PEG
300. PP242 was dissolved in PEG 300. Stock solutions of
rapamycin and U0126 were prepared in DMSO and
further diluted in PBS before injection. Tumor volumes
were measured using caliper measurements every day
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the short axis and b the long axis of the tumor. Animals
were sacrificed after 20 days of treatment and the
tumors were excised and processed for further analysis.
Immunochemistry
Tumor xenografts were carefully removed and rapidly
frozen in OCT compound (Tissue-Teck) on dry ice.
Eight μm transverse sections were cut on a cryostat
(CM 1850, Leica), and processed for immunolabeling
with an anti-Ki-67 (Novocastra) as previously described
[22]. Ki-67 positivity was quantified and expressed as %
of cells positive for Ki-67/total number of cells (300
cells counted per tumor; five tumors in each group).
Statistical analysis
Data were analyzed by Student’st - t e s to ro n ew a y
ANOVA. Values of P < 0.05 were considered statistically
significant.
Results
Concentration-dependent effects of ATP-competitive
inhibitors of mTOR on mTORC1 and mTORC2 activity in
colon cancer cells
The activity of various inhibitors of mTOR was tested on
colon cancer cells that harbor distinct mutations of the
catalytic subunit of PI3K (PI3KCA) [23,24]. LS174T
(PI3KCA mutation on exon 20), DLD-1 (PI3KCA mutation
on exon 9) and SW480 (PI3KCA wild type) colon cancer
cells were treated with increasing concentrations of rapa-
mycin, PP242 [19], a specific mTOR inhibitor, or NVP-
BEZ235 [20], a dual PI3K/mTOR inhibitor for six hours.
Rapamycin, NVP-BEZ235 and PP242 inhibited mTORC1
activity at 10 nM as observed by the dephosphorylation of
S6 ribosomal protein on Western blot analysis (Figure 1).
At higher concentrations (100 nM), NVP-BEZ235 and
PP242 also blocked mTORC2 activity as evidenced by the
dephosphorylation of Akt (Figure 1). In contrast, rapamy-
cin increased Akt phosphorylation consistent with the
removal of a negative feedback loop whereby the inhibi-
tion of mTORC1 induces PI3K/Akt activation [25].
Effect of ATP-competitive inhibitors of mTOR
compared to rapamycin on colon cancer cell
proliferation and survival
To evaluate the activity of rapamycin, NVP-BEZ235
and PP242 on tumor cell growth, colon cancer cell
lines were treated for 48 hours and cell growth was
analyzed by MTS assay. We found that NVP-BEZ235
and PP242 significantly reduced LS174T, DLD-1 and
SW480 cell growth (Figure 2A). Rapamycin also
reduced cell growth of LS174T and DLD-1 cells but to
a lesser extent than PP242 or NVP-BEZ235. Rapamycin
had no effect on SW480 cells (Figure 2A). In addition,
NVP-BEZ235 and PP242 also significantly reduced
tumor growth of a larger panel of colon cancer cell
lines including SW620 and Caco-2 cells (all PI3KCA
wild type) as well as HT-29 and HCT-116 (PI3KCA
mutated) [23]. Rapamycin had no effect on Caco-2 and
SW620 cells and reduced the growth of HT29 and
HCT-116 cells (Additional File 1).
To next investigate whether the effects induced by
mTOR inhibitors on colon cancer cell growth result
from a reduction of cell proliferation, we performed 5-
bromo-2’-deoxyuridine (BrDU) incorporation assay.
NVP-BEZ235 and PP242 significantly decreased BrDU
incorporation in colon cancer cell lines. Similarly to
what we observed on cell growth, rapamycin decreased
BrDU incorporation in LS174T and DLD-1 cells but
not in SW480 cells (Figure 2B). Finally, we also investi-
gated whether mTOR inhibitors induce apoptosis of
colon cancer cells by using a cell death detection
ELISA. We observed that NVP-BEZ235 and PP242
increased colon cancer cell apoptosis in all cell lines
tested. The effect of NVP-BEZ235 was significantly
stronger than PP242. In contrast, rapamycin failed to
induce colon cancer cell apoptosis in LS174T and
SW480 cells and significantly reduced apoptosis in
DLD-1 cells (Figure 2C). Similar results were obtained
by quantifying the apoptotic population of colon cancer
cells following treatments using propidium iodide
staining and flow cytometry analysis (Additional File
2). Taken together, these results show that ATP-com-
petitive inhibitors of mTOR reduce colon cancer cell
proliferation and survival.
ATP-competitive inhibitors of mTOR reduce the growth of
colon cancer xenografts
To evaluate the anticancer effects of mTOR inhibitors in
vivo, nude mice bearing established LS174T or SW480
tumor cell xenografts were treated with rapamycin,
NVP-BEZ235 or PP242 and tumor growth was moni-
tored and compared between each treatment. Rapamy-
cin, NVP-BEZ235 and PP242 reduced the growth of
LS174T tumor xenografts (Figure 3A, B). NVP-BEZ235
and PP242 also slowed the growth of SW480 xenografts.
In contrast, rapamycin had no effect. Nude mice were
administered once a day with rapamycin, NVP-BEZ235
or PP242 at doses that were effective in blocking
m T O R C 1a n dm T O R C 2a sa s s e s s e db yW e s t e r nb l o t
analysis of tumor lysates (Figure 3C).
Effect of ATP-competitive inhibitors of mTOR in
combination with U0126 on colon cancer cell growth
Several studies have shown that the use of mTOR inhi-
bitors induces the activation of MEK/MAPK signaling
pathway which reduces the anticancer effects of mTOR
inhibitors [26,27]. To test whether the inhibition of
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cells, LS174T and SW480 cells were treated with rapa-
mycin, PP242 or NVP-BEZ235 and the phosphorylation
of MAPK was assessed by Western blot. We found that
rapamycin, PP242 and NVP-BEZ235 increased MAPK
phosphorylation in LS174T cells but not in SW480 cells
(Figure 4A). To next address whether targeting MEK/
MAPK signaling pathway would enhance the anticancer
activity of mTOR inhibitors, we treated LS174T and
SW480 colon cancer cells with U0126 [28], a MEK inhi-
bitor, in combination or not with mTOR inhibitors. We
observed that U0126 potentiated the anti-proliferative
and proapoptotic effects of NVP-BEZ235 and PP242 in
both cell lines tested (Figure 4B, C).
Similarly, in vivo, the growth of LS174T or SW480
xenografts was significantly reduced when mice were
treated with rapamycin, PP242 or NVP-BEZ235 in com-
bination with U0126 compared to either treatment alone
(Figure 5A). Western blot analysis of the tumor lysates
showed that, as observed in vitro,m T O Ri n h i b i t o r s
increased MAPK phosphorylation in LS174T but not in
SW480 xenografts. As expected, MAPK phosphorylation
was inhibited by U0126 (Figure 5B). The analysis of the
tumors subjected to each treatment revealed that ATP-
competitive inhibitors of mTOR and U0126 reduced
tumor cell proliferation as evidenced by decreased levels
of Ki-67 staining. The anti-proliferative effects was
increased when mTOR inhibitors were used in combina-
tion with U0126 (Figure 5C). In addition, Western blot
analysis also showed that combining mTOR inhibitors
with U0126 resulted in expression of cleaved caspase-3
which was not observed when mTOR inhibitors and
U0126 were used alone (Figure 5B). Taken together,
these results show that the concomitant pharmacological
blockade of MEK enhances the anticancer activity of
mTOR inhibitors. They also suggest that mTOR inhibi-
tors exert a stronger anti-proliferative effect and induce
apoptosis when used in combination with U0126.
Discussion
mTOR represents a promising target in colon cancer.
Indeed, components of mTOR signaling pathways are
frequently over-expressed and activated in human sam-
ples of colon cancer [10,11]. In addition, in experimental
settings, the inhibition of mTOR components using
siRNA or shRNA results in a marked reduction of colon
cancer cell growth in vitro and tumor xenograft growth
in vivo [10,11,14]. Furthermore, in a transgenic mouse
Figure 1 Effects of rapamycin, NVP-BEZ235 and PP242 on mTORC1 and mTORC2 activity in colon cancer cells. LS174T, DLD-1 and
SW480 colon cancer cells were treated with increasing concentrations of rapamycin, NVP-BEZ235 or PP242 for six hours. Cells were lysed and
analyzed by Western blot for phospho-S6 ribosomal protein and phospho-Akt as a read-out for mTORC1 and mTORC2 activity respectively. Total
S6 ribosomal protein and total Akt were used as loading controls. The illustrated blots are representative of three independent experiments.
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suppressor gene has been mutated, the inhibition of
mTORC1 by the rapamycin analog everolimus,
decreased the formation of intestinal polyps and reduced
mortality of these mice [15].
Initial studies used rapalogs to target mTOR. How-
ever, recent findings have demonstrated that targeting
mTOR signaling pathway with rapalogs might not be
optimal [16]. In fact, rapalogs block only certain
functions of mTORC1 and have no effects on mTORC2.
Moreover, the inhibition of mTORC1 by rapalogs also
results in the activation of proliferative and survival sig-
nals such as the PI3K/Akt and MEK/MAPK signaling
pathways through the removal of a negative feedback
loop [25]. To overcome these limitations, a new class of
mTOR inhibitors has been developed that block the
kinase domain of mTOR and therefore inhibit both
mTORC1 and mTORC2 [16,29]. In this study, we found
Figure 2 Comparison of the effects of NVP-BEZ235 versus PP242 versus rapamycin on colon cancer cell growth, proliferation and
apoptosis. LS174T, DLD-1 and SW480 colon cancer cells were treated with 10 nM of rapamycin, 100 nM of NVP-BEZ235 or 100 nM of PP242 for
48 hours. A: Cell growth was determined using a colorimetric MTS assay. Columns, mean cell growth relative to control of three independent
experiments; bars, SD. B: Cell proliferation was assessed by BrDU incorporation. Results are quantified as percentage of positive cells for BrDU
incorporation. Columns, mean percentage of three independent experiments; bars, SD C: Cell apoptosis was evaluated using a cell death
detection ELISA. Cells were harvested and apoptosis was measured by quantifying DNA fragmentation. Columns, mean enrichment factor at 405
nm of three independent experiments; bars, SD. *, P < 0.05, compared to control or otherwise as specified by brackets.
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Page 5 of 10Figure 3 Effect of Rapamycin, NVP-BEZ235 and PP242 on the growth of LS174T and SW480 tumor xenografts. A:A ne q u a la m o u n to f
LS174T (left panel) or SW480 (right panel) cells were harvested and injected subcutaneously into nude mice. Once the tumor reached 25 mm
3
mice were randomized into four groups and treatments were started with vehicle (Control), rapamycin (R, 1.5 mg/kg/day), NVP-BEZ235 (N, 30
mg/kg/day) or PP242 (P, 60 mg/kg/day). Five mice were included in each group. Tumor volumes were evaluated using caliper measurements
and calculated with the formula V = π/6 × a
2 × b where a is the short axis and b the long axis of the tumor. Points, mean value of tumor
volume; bars, SD. B: After 20 days of treatment, mice were sacrificed, tumor xenografts were harvested and tumor weight was measured.
Columns, mean tumor weight (five tumor xenografts in each group); bars, SD. *, P < 0.05, compared to control. C: Tumor xenografts were lysed
and analyzed by Western blot for phospho-S6 ribosomal protein, total S6 ribosomal protein, phospho-Akt and total Akt. The illustrated blots are
representative of three independent experiments.
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mTOR and NVP-BEZ235, a dual PI3K/mTOR inhibitor,
effectively reduced colon cancer cell proliferation and
survival and the growth of colon cancer tumor
xenografts. Consistent with our findings, a recent study
also demonstrated the efficacy of NVP-BEZ235 in a
genetically engineered mouse model of CRC [30].
Therefore our results provide rationale for the clinical
Figure 4 U0126, a MEK inhibitor, potentiates the anticancer efficacy of ATP-competitive inhibitors of mTOR in vitro. A: LS174T cells (left
panel) or SW480 cells (right panel) were treated with rapamycin (R, 10 nM), NVP-BEZ235 (N, 100 nM), PP242 (P, 100 nM) or DMSO as a control (C)
for 4 hours. Cells were subsequently lysed and lysates were analyzed by Western Blot for phospho-MAPK and MAPK. The illustrated blots are
representative of three independent experiments. B: LS174T and SW480 colon cancer cells were treated with rapamycin (R, 10 nM), NVP-BEZ235 (N,
100 nM) or PP242 (P, 100 nM) for 48 hours in combination or not with U0126 (10 μM). Cell proliferation was assessed by BrDU incorporation.
Results are quantified as percentage of positive cells for BrdU incorporation. Columns, mean percentage of three independent experiments; bars, SD
C: Cells were processed as under panel B and cell apoptosis was evaluated using a cell death detection ELISA. Cells were harvested and apoptosis
was measured by quantifying DNA fragmentation. Columns, mean enrichment factor at 405 nm of three independent experiments; bars, SD.
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Page 7 of 10Figure 5 Antitumoral activity of ATP-competitive inhibitors of mTOR combined with U0126. A: Nude mice bearing LS174T (left panel) or
SW480 (right panel) tumor xenografts were treated with vehicle (C), rapamycin (R, 1.5 mg/kg/day), PP242 (P, 60 mg/kg/day), NVP-BEZ235 (N, 30
mg/kg/day), in combination or not with U0126 (40 μmol/kg/d, i.p.). After 20 days of treatment, tumor volumes were evaluated using caliper
measurements and calculated with the formula V = π/6 × a
2 × b where a is the short axis and b the long axis of the tumor. Columns, mean
tumor volume (five tumor xenografts in each group); bars, SD. *, P < 0.05, compared to control, or otherwise as specified by brackets. B: Tumor
lysates were generated from the harvested xenografts and analyzed for pMAPK, MAPK, cleaved caspase-3 and actin expression. C: Frozen
sections of the harvested tumor xenografts were stained with an anti-Ki-67 antibody. The effect of the different treatments on Ki-67 positivity
was quantified and expressed as % of cells positive for Ki-67/total number of cells (300 cells counted per tumor; five tumors in each group).
Columns, mean % of cells positive for Ki-67 staining; bars, SD. *, P < 0.05 compared to control, or otherwise as specified by brackets.
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colon cancer patients.
We initially hypothesized that ATP-competitive inhibi-
tors of mTOR would produce anticancer activity only in
cells harboring PI3KCA mutations. To support this
hypothesis it was previously reported that NVP-BEZ235
was effective in PI3K but not in KRAS mutated breast
cancer cells and similar findings were reported in a
murine model of lung cancer [31,32]. However, we
observed here that ATP-competitive inhibitors of
mTOR exhibited anticancer effects on both PI3KCA
mutated as well as on PI3KCA wild type colon cancer
cells. Consistent with our findings, NVP-BEZ235 is
effective in a mouse model of sporadic PI3KCA wild
type CRC suggesting that the antitumor activity of ATP-
competitive inhibitors of mTOR is not restricted to
PI3KCA mutated colon cancer cells [30].
The anticancer efficacy ofN V P - B E Z 2 3 5a n dP P 2 4 2
was both in vitro and in vivo superior to rapamycin. It
is however worth noting that despite blocking mTORC1
activity in vivo, the doses of rapamycin that we used
(1.5 mg/kg/day) were lower than those reported by
other groups (5 mg/kg/day and 20 mg/kg/day) [33,34].
Therefore a comparison between ATP-competitive inhi-
bitors of mTOR and higher concentrations of rapamycin
is needed to conclude that ATP-competitive inhibitors
of mTOR are more efficient than rapamycin. Neverthe-
less, similar to what we found, it was reported in renal
cell carcinoma, that the anticancer efficacy of NVP-
BEZ235 was superior to rapamycin used at 3.5 mg/kg/
day [35].
Our findings also suggest that ATP-competitive inhibi-
tors of mTOR display a broader anticancer activity than
rapalogs. We found that while rapamycin had no effect on
SW480 colon cancer cells, PP242 and NVP-BEZ235
reduced SW480 cell proliferation and survival as well as
the growth of SW480 xenografts. Similarly, it was reported
that blocking mTORC1 by rapamycin or by the use of rap-
tor siRNA had no effect on the proliferation of SW480
cells. In contrast, targeting mTORC2 with rictor siRNA
efficiently reduced SW480 cell proliferation [10]. There-
fore, by blocking mTORC2 in addition to mTORC1, the
anticancer activity of ATP-competitive inhibitors of
mTOR appear to be broader than rapamycin.
Emerging evidence has shown that blocking mTORC1
results in the removal of a negative feedback loop result-
ing in the activation of the PI3K/Akt and MEK/MAPK
signaling pathways that counteract the anticancer effi-
cacy of mTOR inhibitors [25]. In our study, we observed
that ATP-competitive inhibitors of mTOR increased
MAPK phosphorylation in LS174T cells (Figure 4a).
Similar effects were reported in other cell types includ-
ing renal cancer cells, Waldenstrom macroglobulinemia
cells, sarcoma cells and endothelial cells [35-38]. We
further observed that targeting MAPK with a MEK inhi-
bitor in combination with mTOR inhibitors resulted in
synergistic inhibition of LS174T and SW480 colon can-
cer cell growth (Figure 4b-d). Noteworthy, we found
that ATP-competitive inhibitors of mTOR did not
increase MAPK phosphorylation in SW480 suggesting
that MEK inhibitors would potentiate the anticancer
efficacy of mTOR inhibitors regardless of whether
mTOR inhibitors increase MAPK phosphorylation.
Conclusions
Overall, our study shows that ATP-competitive inhibi-
tors of mTOR efficiently reduced the growth of colon
cancer cells both in vitro and in vivo. In addition, it also
shows that the anticancer efficacy of ATP-competitive
inhibitors of mTOR is potentiated by the simultaneous
pharmacological blockade of the MEK/MAPK signaling
pathway in colon cancer cells. Therefore, ATP-competi-
tive inhibitors represent promising agents in the treat-
ment of CRC that warrant to be tested in clinical trials.
Additional material
Additional file 1: Effects of rapamycin, PP242 and NVP-BEZ235 on
the growth of Caco-2, SW620, HT29 and HCT-116 colon cancer cells.
Caco-2, SW620, HT29 and HCT-116 colon cancer cells were treated with
10 nM of rapamycin, 100 nM of PP242, 100 nM of NVP-BEZ235 or DMSO
as a control for 48 hours. Cell growth was determined using a
colorimetric MTS assay. Columns, mean cell growth relative to control of
three independent experiments; bars, SD. P < 0.05, compared to control
or otherwise as specified by brackets.
Additional file 2: Effects of rapamycin, PP242 and NVP-BEZ235 on
the growth of Caco-2, SW620, HT29 and HCT-116 colon cancer cells.
Caco-2, SW620, HT29 and HCT-116 colon cancer cells were treated with
10 nM of rapamycin, 100 nM of PP242, 100 nM of NVP-BEZ235 or DMSO
as a control for 48 hours. Cell growth was determined using a
colorimetric MTS assay. Columns, mean cell growth relative to control of
three independent experiments; bars, SD. P < 0.05, compared to control
or otherwise as specified by brackets.
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subunit of phosphatidylinositol 3-kinase; DMSO: Dimethyl sulfoxide; PBS:
Phosphate buffered saline.
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